18177 New Thinking on GVHD Management in HSCT Recipients: Focus on Underlying Immunology and Innovative Therapeutics
In this activity, based on a recent live symposium at the 2018 BMT Tandem Meetings, experts in hematology-oncology and bone marrow transplantations take a deep dive into the underlying immunology of graft-versus-host disease (GVHD) and the latest evidence with approved and emerging classes of innovative therapeutics, as well as provide expert insight on the practical application of these advancements as prophylaxis or for treatment of acute and chronic, steroid-nonresponsive, and previously untreated GVHD.
This activity has been designed to meet the educational needs of hematologist-oncologists, oncologists, BMT specialists and BMT nurse specialists, and other clinicians involved in the care of patients undergoing HCT.
- Describe the underlying immunology of post-transplant GVHD, and the rationale for and mechanisms of novel therapies in the management of GVHD
- Summarize efficacy and safety evidence on novel therapeutic options, such as JAK1/2 inhibitors and BTK inhibitors, for GVHD prophylaxis and treatment in HSCT recipients
- Recommend ongoing clinical trials assessing new strategies and combinations of agents to eligible patients with acute or chronic, steroid-naïve or steroid-refractory GVHD in the HSCT setting
David Miklos, MD, PhD
Associate Professor of Medicine
Clinical Director, Cancer Cell Therapy Program
Stanford University, Division of Blood and Marrow Transplantation
John F. DiPersio, MD, PhD
Virginia E. and Samuel J. Golman Professor in Medicine
Chief, Division of Oncology
Deputy Director, Alvin J. Siteman Cancer Center
Professor of Medicine, Pathology & Immunology
Washington University School of Medicine
St. Louis, Missouri
All persons in control of content have no relevant financial relationships to disclose.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of The Medical College of Wisconsin and PeerView Institute for Medical Education. The Medical College of Wisconsin is accredited by the ACCME to provide continuing medical education for physicians.
AMA Credit Designation Statement:
The Medical College of Wisconsin designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Hours of Participation for Allied Health Care Professionals:
The Medical College of Wisconsin designates this activity for up to 1.0 hours of participation for continuing education for allied health professionals.
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.